Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Rating of “Buy” by Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company.

Several analysts have recently commented on BAYRY shares. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd.

Bayer Aktiengesellschaft Stock Up 0.9%

Shares of BAYRY opened at $14.35 on Friday. The company has a market capitalization of $56.38 billion, a P/E ratio of -28.13, a PEG ratio of 4.46 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70. Bayer Aktiengesellschaft has a one year low of $7.48 and a one year high of $15.23. The business’s 50 day simple moving average is $13.99 and its 200-day simple moving average is $12.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.The firm had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.